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1. INTRODUCTION {#mgg3504-sec-0005}
===============

Colorectal cancer (CRC) is the third most common cancer in the world and the fifth most prevalent cancer type in China, causing 376.3 thousand new patients and 191.0 mortality a year (Chen, Xu, et al., [2016a](#mgg3504-bib-0002){ref-type="ref"}; Chen, Zheng, et al., [2016b](#mgg3504-bib-0003){ref-type="ref"}; Wang et al., [2017](#mgg3504-bib-0013){ref-type="ref"}). The occurrence of CRC is directly correlated with the abnormal immunological microenvironment. It has been reported that the immunotherapy on cancer, including CRC, is very effective, which allows us to investigate the immune repertoire study in CRC patients (Hope et al., [2017](#mgg3504-bib-0006){ref-type="ref"}). Further study on CRC patients in respect to change in immunological microenvironment with origin as well as the prognosis of cancer is a one of the significant methods for early detection of biomarkers as well as identifying the target for immunotherapy. It is well studied that the first‐tier treatment of colorectal cancer is timely surgical interventions or total colectomy (Adelson et al., [2018](#mgg3504-bib-0001){ref-type="ref"}). Hence, different anesthesia pattern would have a significant role for the prognosis of colorectal cancer. Till date, there is no study has been performed for the comparison of colorectal cancer patients and healthy controls' in terms of TRCs and the different methods of anesthesia.

T cells are the active cell population‐mediating cellular immune response and function as an important component in humoral immune system activation response. T‐cell receptors (TCRs) are the antigen recognition part on T‐cell membrane, which is composed of α and β chain, or γ and δ chain. Complementarity‐determining region 3 (CDR3) is a critical region in TCR on both the chains, responsible for specifically recognize and bind antigen peptide. Each T cell has its own unique CDR3 sequence. According to the homology of CDR3 variable region (V) gene sequence, TCR Vβ genes are divided into 24 families. Testing of each Vβ gene family\'s CDR3 spectra could reflect the clonal expansion of T cells (Luo et al., [2014](#mgg3504-bib-0008){ref-type="ref"}).

In this study, we applied high‐throughput next‐generation sequencing (NGS) to elucidate the immune repertoire status among sporadic colorectal cancer patients (T1M0N0; Stage I) in different time points (1 day before surgery, 3 days' after surgery, and 7 days after surgery) with different anesthesia methods to patients and healthy controls. Then, the distribution of CDR3 length in preoperative patients and healthy controls was studied. Additionally, highly expanded clone distribution in preoperative patients, healthy controls, and postoperative patients at different time points with different anesthesia (TIVA and CGEA) methods has been compared in this study. In order to understand the mechanism of CRC immune exchange, TRBV, TRBJ gene repertoires between preoperative patients and healthy controls would also be studied.

2. MATERIALS AND METHODS {#mgg3504-sec-0006}
========================

2.1. Patients and controls {#mgg3504-sec-0007}
--------------------------

Whole blood samples from 19 CRC patients and five healthy controls were collected at The Second Medical College of Jinan University (Shenzhen People\'s Hospital), Shenzhen, China, and PBMCs were extracted. We collected the PMBCs of 10 colon cancer patients, who had taken the TIVA anesthesia pattern, at 1 day preoperative, 3 days' postoperative, and 7 days' postoperative time point, respectively. The PMBCs of nine CRC patients, who had taken the CEGA anesthesia, at 1 day preoperative, 3 days' postoperative, and 7 days' postoperative time point were collected. The Ethical Committee of the Department of Anesthesiology, Shenzhen People\'s Hospital, 2nd Clinical Medical College of Jinan University, Shenzhen, Guangdong, China, reviewed and approved our study protocol in compliance with the Helsinki Declaration.

2.2. T‐cell isolation and DNA extraction {#mgg3504-sec-0008}
----------------------------------------

Informed consent was obtained from all the participants in our study. T‐cell isolations were performed using superparamagnetic polystyrene beads (Miltenyi) coated with monoclonal antibodies specific for T cells. DNA was prepared from 0.5 to 2 × 106 T cells from each sample, which was sufficient for analyzing the diversity of TCRV in the T‐cell subsets. DNA was extracted from PBMCs using GenFIND DNA (Agencourt, Beckman Coulter, Brea, CA, USA) extraction kits following the manufacturer\'s instructions.

2.3. Multiplex‐PCR amplification of the TCR CDR3 region {#mgg3504-sec-0009}
-------------------------------------------------------

The TCR CDR3 region was defined according to International ImMunoGeneTics collaboration, starting with the second conserved cysteine encoded by the 39 portions of the V gene segment and ending with the conserved phenylalanine encoded by the 59 portions of the J gene segment. To generate the template library for Genome Analyzer, a multiplex‐PCR system was designed to amplify rearranged TCR CDR3 regions from genomic DNA using 45 forward primers, each is specific to a functional TCR V segment, and 13 reverse primers, each is specific to a TCR J segment. The forward and reverse primers contain, at their five ends, the universal forward and reverse primer sequences, respectively, which are compatible with GA2 cluster station solid‐phase PCR. After amplification and selection, the products were purified using QIAquick PCR Purification Kit. The final library was quantitated in two ways: by determining the average molecule length using the Agilent 2100 bioanalyzer instrument (Agilent DNA 1000 Reagents) and by real‐time quantitative PCR (QPCR; TaqMan Probe). The libraries were amplified with cBot to generate the cluster on the flow cell, and the amplified flow cell was pair‐end (PE) sequenced using a Hiseq2500 instrument, with a read length of 100 as the most frequently used sequencing strategy.

2.4. High‐throughput sequencing and data analysis {#mgg3504-sec-0010}
-------------------------------------------------

The PCR products were sequenced using an Illumina Genome Analyzer, and the sequencing quality of these reads was evaluated by the formula shown below. The quality of the HiSeq sequencing ranged from 0 to 40 and was used for filtering out low‐quality reads. First, we filtered the raw data, including adapter contamination. Reads with an average quality score lower than 15 (Illumina 0--41 quality system) were removed, and the proportion of N bases was not more than 5% (sequences with higher values were also removed). Next, a few bases with low quality (lower than 10) were trimmed; the quality score was expected to be over 15 after trimming, and the remaining sequence length was expected to be more than 60 nt. After filtering, PE read pairs were merged into one contig sequence in two steps: (a) by aligning the tail parts of two sequences and assessing the identity (BGI developed software COPE v1.1.3), with at least 10 bases of overlap required and the overlapping section having 90% base match; (b) as different primers might result in sequences of different lengths, some might be very short (\<100 bp) and such reads were merged by aligning the head part of the sequence (BGI developed software FqMerger). In this way, we obtained the merged contig sequences and the length distribution plot. Subsequently, we used miTCR, developed by MiLaboratory (<https://mitcr.milaboratory.com/downloads/>) for the alignment. This program has an automated adjustment mechanism for errors introduced by sequencing and PCR and will provide alignment statistical information, such as the CDR3 expression and INDEL. After alignment, we utilized the following method for the sequence structural analysis: (a) We calculated the number of each nucleotide and analyzed the proportion at each position; (b) according to the last position of the V gene, start site of the D gene, end site of the D gene, and start site of the J gene after alignment, we retrieve the INDEL (insertion and deletion) introduced during V--D--J recombination; (c) nucleotides were translated into amino acids. According to the identity of each sequence after alignment, the expression level of each clone was clear and calculated. The expression of each distinct DNA sequence, amino acid sequence, and V--J combination was also identified. In addition, to measure the diversity of each sample, we calculated the distinct clone number, Simpson coefficient, and Shannon--Waver coefficient based on different resolutions of distinct DNA sequences, amino acid sequences, and V--J combinations. The expression level of each sample was also calculated at different resolutions of distinct DNA sequence, amino acid sequence, and V--J combination. Moreover, we constructed the specific expression graph and plotted a heatmap according to the V--J combination profile. The diversity of the TCR repertoire was calculated based on the Simpson index of diversity (Ds) and the Shannon--Wiener index (*H*).

2.5. Statistical analysis {#mgg3504-sec-0011}
-------------------------

Because of the small sample size in this study, the analysis of differences among the data groups was performed with the *t* test. *p* values \<0.05 were considered significant. The statistical analyses were conducted with GraphPad Prism software (GraphPad Software, San Diego, CA, USA).

3. RESULTS {#mgg3504-sec-0012}
==========

3.1. Sequencing data summary {#mgg3504-sec-0013}
----------------------------

A total of 19 colorectal cancer patients and five healthy controls were recruited for this study. Blood sample from 1 day preoperative, 1 day postoperative, 3 days' postoperative, and 7 days' postoperative was collected. We obtained an average of 713,362 sequencing reads per sample (Figure [1](#mgg3504-fig-0001){ref-type="fig"}). The mean unknown sequence number is 15,856, and the mean immune sequence number is 697,505. The productive sequence number and the nonproductive sequence number are 519,165 and 178,340, respectively. And *In‐frame* sequences number and *Out‐of‐frame* sequences number are 539,825 and 151,114, respectively. The total CDR3 sequence number, unique CDR3 nt sequence number, and Unique CDR3 aa sequence number are 505,707, 54,921, and 47,892 respectively (Table [1](#mgg3504-tbl-0001){ref-type="table"}).

![The details of data interpretation pipeline](MGG3-7-na-g001){#mgg3504-fig-0001}

###### 

The sequencing data of preoperation, postoperation colorectal cancer (CRC) patients, and normal controls

  Sample          Total read number   Immune sequence number   Unknown sequence number   Productive sequence number   Nonproductive sequence number   In‐frame sequence number   Out‐of‐frame sequence number   Total CDR3 sequence number   Unique CDR3 nt sequence number   Unique CDR3 aa sequence number
  --------------- ------------------- ------------------------ ------------------------- ---------------------------- ------------------------------- -------------------------- ------------------------------ ---------------------------- -------------------------------- --------------------------------
  AC1             1,024,851           1,018,261                6,590                     763,607                      254,654                         791,978                    222,451                        749,378                      51,515                           44,194
  AC2             915,539             907,787                  7,752                     612,514                      295,273                         636,437                    267,323                        594,790                      23,903                           19,362
  AC3             816,031             809,723                  6,308                     596,926                      212,797                         623,456                    182,764                        585,065                      34,505                           28,231
  AD1             585,142             579,428                  5,714                     434,691                      144,737                         451,489                    124,876                        423,863                      42,681                           37,572
  AD2             472,688             467,463                  5,225                     308,195                      159,268                         322,541                    142,372                        296,522                      21,470                           18,205
  AD3             491,946             487,345                  4,601                     358,566                      128,779                         372,844                    111,952                        347,880                      35,859                           31,372
  AE1             689,228             686,592                  2,636                     515,251                      171,341                         536,573                    148,702                        506,671                      44,802                           38,574
  AE2             652,635             648,916                  3,719                     454,498                      194,418                         473,915                    173,199                        445,088                      25,864                           21,307
  AE3             618,329             615,743                  2,586                     467,389                      148,354                         486,543                    127,915                        459,618                      40,967                           35,152
  AF1             638,916             635,461                  3,455                     480,936                      154,525                         507,267                    126,411                        459,509                      57,346                           50,990
  AF2             576,782             574,195                  2,587                     413,875                      160,320                         435,968                    136,955                        393,742                      27,561                           22,786
  AF3             556,098             553,235                  2,863                     411,855                      141,380                         432,611                    119,126                        393,503                      37,868                           32,556
  AH1             684,804             679,686                  5,118                     508,178                      171,508                         525,236                    151,717                        500,960                      32,634                           28,647
  AH2             612,272             607,843                  4,429                     418,215                      189,628                         431,472                    174,073                        411,668                      13,414                           11,262
  AH3             553,362             548,243                  5,119                     401,398                      146,845                         416,356                    129,142                        394,970                      26,871                           22,970
  AJ1             888,349             881,175                  7,174                     666,063                      215,112                         691,334                    185,866                        655,889                      48,562                           41,840
  AJ2             571,779             565,678                  6,101                     415,792                      149,886                         430,800                    131,830                        407,950                      23,184                           19,397
  AJ3             593,718             587,471                  6,247                     397,681                      189,790                         416,218                    168,132                        388,181                      24,027                           19,801
  BC1             457,877             456,003                  1874                      365,329                      90,674                          381,349                    73,765                         359,382                      29,517                           25,085
  BC2             493,920             491,375                  2,545                     378,912                      112,463                         395,000                    95,022                         370,358                      22,213                           18,557
  BC3             635,015             631,465                  3,550                     486,999                      144,466                         508,131                    121,623                        478,226                      28,547                           23,598
  BD1             668,144             664,884                  3,260                     540,400                      124,484                         558,052                    105,180                        531,880                      18,627                           15,004
  BD2             517,884             514,866                  3,018                     374,193                      140,673                         391,179                    122,250                        366,294                      18,125                           14,729
  BD3             444,360             440,878                  3,482                     292,794                      148,084                         304,829                    134,361                        284,279                      14,105                           11,501
  BF1             495,271             490,136                  5,135                     381,063                      109,073                         398,525                    89,012                         373,918                      35,855                           31,343
  BF2             553,048             546,105                  6,943                     347,777                      198,328                         367,448                    175,352                        335,777                      22,811                           18,999
  BF3             929,050             922,164                  6,886                     687,932                      234,232                         722,551                    196,043                        674,703                      37,951                           31,204
  BG1             653,871             650,887                  2,984                     499,435                      151,452                         519,916                    129,541                        491,033                      39,035                           33,055
  BG2             555,950             549,055                  6,895                     328,977                      220,078                         344,390                    201,461                        317,677                      21,045                           17,857
  BG3             455,728             449,852                  5,876                     257,201                      192,651                         271,112                    175,899                        246,750                      17,082                           14,160
  BH1             969,580             963,580                  6,000                     758,935                      204,645                         787,303                    173,146                        746,555                      43,678                           36,545
  BH2             808,748             803,701                  5,047                     638,897                      164,804                         661,579                    139,513                        629,097                      35,323                           29,200
  BH3             586,924             580,323                  6,601                     398,425                      181,898                         413,850                    163,541                        387,228                      18,139                           14,569
  BI1             577,915             574,247                  3,668                     458,549                      115,698                         474,530                    97,725                         441,438                      38,294                           32,526
  BI2             471,440             466,428                  5,012                     343,870                      122,558                         356,712                    107,489                        328,694                      20,062                           16,528
  BI3             583,748             576,360                  7,388                     400,607                      175,753                         417,237                    155,274                        379,554                      36,364                           31,090
  HHT1            1,084,617           1,035,772                48,845                    938,621                      97,151                          961,208                    52,913                         917,434                      357,213                          323,645
  HHT2            1,040,725           987,555                  53,170                    891,697                      95,858                          913,539                    50,317                         869,464                      377,925                          343,288
  HHT3            929,379             885,492                  43,887                    806,168                      79,324                          823,340                    42,651                         787,594                      309,389                          278,567
  HHT4            2,146,006           1,877,696                268,310                   1,186,570                    691,126                         1,242,699                  547,083                        1,129,853                    54,996                           44,183
  HHT5            1,246,186           1,184,666                61,520                    896,805                      287,861                         935,340                    221,721                        871,592                      42,462                           34,137
  Average value   713362.3            697505.7                 15856.59                  519165.5                     178340.2                        539825.8                   151114.3                       505,708                      54921.73                         47892.39

AC1, AD1, AE1, AF1, and AJ1 represent sequencing data from PMBCs of CRC patients at 1 day preoperation in TIVA group. AC2, AD2, AE2, AF2, and AJ2 means sequencing data from PMBCs of CRC patients at 3 days' postoperation in TIVA group. AC3, AD3, AE3, AF3, and AJ3 represent sequencing data from PMBCs of CRC patients at 7 days' postoperation in TIVA group.

BC1, BD1, BF1, BJ1, BH1, and BI1 represents sequencing data from PMBCs of CRC patients at 1 day preoperation in CEGA group. BC2, BD2, BF2, BJ2, BH2, and BI2 represent sequencing data from PMBCs of CRC patients at 3 days' postoperation in CEGA group. BC3, BD3, BF3, BJ3, BH3, and BI3 represent sequencing data from PMBCs of CRC patients at 7 days' postoperation in CEGA group.

HHT1, HHT2, HHT3, HHT4, and HHT5 represent data from PMBCs of normal controls.

CDR3: complementarity‐determining region 3.
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3.2. CDR3 length distribution pattern {#mgg3504-sec-0014}
-------------------------------------

The length distribution of the TCR CDR3 is an important determinant of T‐cell repertoire diversity. In this study, we first assessed the length distribution of TCR CDR3 sequences (aa) in the preoperative group and healthy control group (Figure [2](#mgg3504-fig-0002){ref-type="fig"}). TCR CDR3 sequence length in preoperative group was significantly higher compared to those in the NC group with the amino acid length 1 (*p* = 0.028), 28 (*p* = 0.026), 29 (*p* = 0.0064), and 30 (*p* = 0.00078).

![Complementarity‐determining region 3 length distribution in healthy controls and preoperation colorectal cancer (CRC) patients. "Pink" bar represents the value of healthy controls', and "green" bar represents the value of preoperative CRC patients'. Black triangle represents the significant different (*p* \< 0.05)](MGG3-7-na-g002){#mgg3504-fig-0002}

We draw the Gaussian distribution curve for each sample, and the goodness of fit was quantified by *R* ^2^, which ranges from 0 to 1 (from lowest fitness to highest fitness). *R* ^2^ values were calculated for each sample and compared between the preoperative CRC patients and healthy controls (*p* = 0.0016; Figure [3](#mgg3504-fig-0003){ref-type="fig"}).

![*R* ^2^ comparison between the preoperation colorectal cancer (CRC) patients and healthy controls. H represents value of the healthy controls, and pre represents value of the preoperation CRC patients](MGG3-7-na-g003){#mgg3504-fig-0003}

3.3. Highly expanded clones and TCR repertoires diversity {#mgg3504-sec-0015}
---------------------------------------------------------

The expression level of each unique clone is another major measurement or index for immune diversity. After aligning to the human genome reference, the expression level of each clone is calculated. In this study, the TCR clones with frequency above 0.5% of total reads in a sample were defined as highly expansion clone (HEC). The comparison of HEC number between preoperative group and healthy control group showed significant higher HEC ratio in preoperative group (Figure [4](#mgg3504-fig-0004){ref-type="fig"}a). In the TIVA group, HEC number of 3 days' postoperative samples was higher than 1 day preoperative group (*p* = 0.021) and also higher than the value of 7 days' postoperative group (*p* = 0.018; Figure [4](#mgg3504-fig-0004){ref-type="fig"}b).

![(a) Comparison of highly expansion clone (HEC) number distribution between healthy controls' and preoperative colorectal cancer (CRC) patients'. H represents HEC number of healthy controls, and pre represents HEC number of preoperation CRC patients. (b) Comparison of HEC number of CRC patients who takes TIVA. A1 represents the value of PMBCs collected at 1 day preoperation. A2 represents the value of PMBCs collected at 3 days' postoperation. A3 represents the value of PMBCs collected at 7 days' postoperation. (c) Comparison of HEC ratio of CRC patients who takes TIVA. A1 represents the value of PMBCs collected at 1 day preoperation. A2 represents the value of PMBCs collected at 3 days' postoperation. A3 represents the value of PMBCs collected at 7 days' postoperation. (d) Comparison of HEC ratio between TIVA and CEGA groups at different time points. A represents TIVA groups, and B represents CEGA. Time line 1 represents the value of PMBCs taken from 1 day preoperation, 3 days' postoperation, and 7 days' postoperation. (e) Comparison of HEC ratio between TIVA and CEGA groups at different time points. (A) represents TIVA groups, (B) represents CEGA. Time line 1 represents the value of PMBCs taken from 1 day preoperation, 3 days' postoperation, and 7 days' postoperation](MGG3-7-na-g004){#mgg3504-fig-0004}

The HEC ratio of TIVA group also showed similar distribution of HEC number; the 3 days' postoperative group showed higher HEC than 1 day preoperative group (*p* = 0.031), higher than the HEC ratio of 7 days' postoperative group (*p* = 0.015). The HEC ratio of 7 days' postoperative group was lower than 1 day preoperative group (*p* = 0.022; Figure [4](#mgg3504-fig-0004){ref-type="fig"}c). To further study the difference in effect of TIVA and CGEA on immune repertoire, we also compared the HEC number and HEC ratio at the 3 different time period. The results showed there was no significant difference in the effect between the two anesthesia methods. (Figure [4](#mgg3504-fig-0004){ref-type="fig"}d,e). The comparison of HEC number and HEC ratio at different time period in CGEA group showed no significant difference (Figure [5](#mgg3504-fig-0005){ref-type="fig"}).

![(a) Comparison of highly expansion clone (HEC) number of colorectal cancer (CRC) patients who takes CEGA anesthesia. A1, represents the value of PMBCs collected at 1 day preoperation. A2 represents the value of PMBCs collected at 3 days' postoperation. A3 represents the value of PMBCs collected at 7 days' postoperation. (b) Comparison of HEC ratio of CRC patients who takes CEGA anesthesia. A1 represents the value of PMBCs collected at 1 day preoperation. A2 represents the value of PMBCs collected at 3 days' postoperation. A3 represents the value of PMBCs collected at 7 days' postoperation](MGG3-7-na-g005){#mgg3504-fig-0005}

To further understand the percentage of shared HECs, we then analyzed the top 60 highly used amino acids and nucleotide sequences in 0.5% used clones of CRC patients and healthy controls. According to Figure [6](#mgg3504-fig-0006){ref-type="fig"}, there were highly shared sequences in CRC patients than in healthy controls.

![(a) Percentage of top 60 used complementarity‐determining region 3 (CDR3) nucleotides. AC1, AD1, AE1, AF1, AH1, AJ1, BC1, BD1, BF1, BG1, BG1, BH1, and BI1 are all preoperation colorectal cancer (CRC) patients. HHT01, HHT02, HHT03, HHT04, and HHt05 are all healthy controls. (b) Percentage of top 60 used CDR3 amino acids. AC1, AD1, AE1, AF1, AH1, AJ1, BC1, BD1, BF1, BG1, BG1, BH1, and BI1 are all preoperation CRC patients. HHT01, HHT02, HHT03, HHT04, and HHt05 are all healthy controls](MGG3-7-na-g006){#mgg3504-fig-0006}

3.4. Comparison of TRBV and TRBJ gene repertoires between preoperative patients and healthy controls {#mgg3504-sec-0016}
----------------------------------------------------------------------------------------------------

To determine the disease‐specific TCR repertoire characteristics, we compared the expression levels of TRBV and TRBJ genes of preoperative patients and healthy controls. In comparison with TRBV gene between preoperative patients and healthy controls, TRBV11‐2 (*p* = 0.016), TRBV12‐1 (*p* = 0.0068), TRBV16 (*p* = 0.0032), TRBV3‐2 (*p* = 0.0096), TRBV4‐2 (*p* = 0.03), TRBV4‐3 (*p* = 0.048), TRBV5‐4 (*p* = 0.011), TRBV6‐8 (*p* = 0.038), TRBV7‐8 (*p* = 0.042), and TRBV7‐9 (*p* = 0.023) usage showed significant difference (Figure [7](#mgg3504-fig-0007){ref-type="fig"}a). In contrast, the differentiation of TRBJ gene between preoperative and healthy control patients showed significant difference in the usage of TRBJ1‐3 (*p* = 0.035), TRBJ2‐2 (*p* = 0.00053), and TRBJ2‐5 (*p* = 0.023; Figure [7](#mgg3504-fig-0007){ref-type="fig"}b). Analysis of top 20 used TRBV genes was performed; TRBV7‐8, TRBV7‐9, and TRBV9 were well used in both CRC patients and healthy controls. TRBV2, TRBV12, TRBV19, TRBV20‐1, and TRBV24‐1 were poorly used in either CRC patients or healthy controls (Figure [8](#mgg3504-fig-0008){ref-type="fig"}).

![(a) Comparison of TRBV gene usage between preoperation patients and healthy controls. PH represents TRBV gene usage percentage of healthy controls, PRE, represents TRBV gene usage percentage of preoperation colorectal cancer (CRC) patients. Black triangle represents significant difference between healthy controls and preoperation CRC patients' TRBV gene usage. (b) Comparison of TRBJ gene usage between preoperation patients and healthy controls. PH represents TRBV gene usage percentage of healthy controls, and PRE represents TRBV gene usage percentage of preoperation CRC patients. Black triangle represents significant difference between healthy controls and preoperation CRC patients' TRBV gene usage](MGG3-7-na-g007){#mgg3504-fig-0007}

![Heatmap of TOP 20 TRBV usage gene. A1 represents the value of PMBCs collected at 1 day preoperation. A2 represents the value of PMBCs collected at 3 days' postoperation. A3 represents the value of PMBCs collected at 7 days' postoperation](MGG3-7-na-g008){#mgg3504-fig-0008}

4. DISCUSSION {#mgg3504-sec-0017}
=============

As the 3rd leading cause of tumor mortality, colorectal cancer is a well‐known and well‐studied type of cancer. The previous studies on colorectal cancer\'s biomarkers, surgery methods, metastatic mechanisms, target medicine‐related researches, anesthesia methods, immune repertoires, all have revealed the fundamental data (Daher, Chouillard, & Panis, [2014](#mgg3504-bib-0004){ref-type="ref"}; Deschoolmeester, Baay, Specenier, Lardon, & Vermorken, [2010](#mgg3504-bib-0005){ref-type="ref"}; Pan et al., [2017](#mgg3504-bib-0010){ref-type="ref"}; Tsai et al., [2010](#mgg3504-bib-0012){ref-type="ref"}). Here, we recruited 19 CRC patients and five healthy controls to study the difference in immune repertoire status among colorectal cancer patient at preoperative, postoperative, and healthy controls.

In comparison with CDR3 length distribution between preoperative colorectal patients and healthy controls showed there was significant difference between these two groups. This result again elucidated the immune repertoire effect on colorectal cancer patients which corresponds to the similar finding of previously reported CRC immune correlation study 1 (Li et al., [2016](#mgg3504-bib-0007){ref-type="ref"}; Nakanishi et al., [2016](#mgg3504-bib-0009){ref-type="ref"}).

Another well used factor to evaluate the immune repertoire status is HECs; the comparison between preoperative group and healthy control group again showed the significant higher HEC ratio and HEC number in CRC patients than the healthy control group, which could be the result of cancer‐immune reaction (Chen, Xu, et al., [2016a](#mgg3504-bib-0002){ref-type="ref"}; Chen, Zheng, et al., [2016b](#mgg3504-bib-0003){ref-type="ref"}). In addition, we found that TIVA patient group has significantly different HEC numbers and HEC ratios at different time period (1 day preoperative, 3 days' postoperative, and 7 days' postoperative), which could be a milestone for understanding and the management of the postoperation medical care. However, there were no differences in CGEA patient groups at different time period. Although there is possible effect of surgery on patients' immune system, the difference in distribution of TIVA and CEGA on 3 days' postsurgery and 7 days' postsurgery patient group could provide more solid evidence to prove CEGA\'s potential advantage on immune repertoire balance. Then, the further hypothesis is to prove CGEA anesthesia has less effect on patients' immune repertoires than the TIVA anesthesia or not despite the limited research samples, this could be a prestudy to further elucidate the effect of TIVA and CGEA on immune repertoires.

The random assortment of the V, (D), J gene segments provides the basic structural frames for antibody variable region to recognize specific antigen. Till now, only few experiments have performed the usage feature of V, (D), J gene segments. In the present study, all TRBV and TRBJ genes were deeply sequenced to study the potential specific higher usage. Between the patients and healthy control groups, TRBV11‐2 (*p* = 0.016), TRBV12‐1 (*p* = 0.0068), TRBV16 (*p* = 0.0032), TRBV3‐2 (*p* = 0.0096), TRBV4‐2 (*p* = 0.03), TRBV4‐3(*p* = 0.048), TRBV5‐4(*p* = 0.011), TRBV6‐8(*p* = 0.038), TRBV7‐8 (*p* = 0.042), and TRBV7‐9(*p* = 0.023) usage showed significant difference. TRBV11‐2 (*p* = 0.016), TRBV12‐1 (*p* = 0.0068), TRBV16 (*p* = 0.0032), TRBV3‐2 (*p* = 0.0096), TRBV4‐2 (*p* = 0.03), TRBV4‐3 (*p* = 0.048), TRBV5‐4 (*p* = 0.011), TRBV6‐8 (*p* = 0.038), TRBV7‐8 (*p* = 0.042), and TRBV7‐9 (*p* = 0.023) usage showed significant difference. The higher usage genes provide the potential to target in specific immune‐related targeted medical approach.

In conclusion, we elucidated the different immunology repertoires in colorectal cancer patients and healthy controls. We further studied the effect of two anesthesia methods TIVA and CGEA on patients' immune repertoires. We also studied TRBV and TRBJ genes which provided several potential targets for immune system‐targeted medicine for colorectal cancer. The immune repertoire will be a powerful tool for predicting the colorectal cancer surgery prognosis and identifying the targeted medicine.
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